MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: MSK-2206|DRUG: Exemestane|DRUG: Goserelin
Sponsor: Vanderbilt-Ingram Cancer Center